Browsing by Author "Turk, H. M."
Now showing 1 - 3 of 3
- Results Per Page
- Sort Options
Item Clinical Benefits of First-Line (1L) Cemiplimab Monotherapy by PD-L1 Expression Levels in Patients With Advanced NSCLC(2021) Kilickap, S.; Sezer, A.; Gumus, M.; Bondarenko, I.; Ozguroglu, M.; Gogishvili, M.; Turk, H. M.; Cicin, I.; Bentsion, D.; Gladkov, O.; Clingan, P.; Sriuranpong, V.; Rizvi, N.; Li, S.; Lee, S.; Makharadze, T.; Paydas, S.; Nechaeva, M.; Seebach, F.; Weinreich, D.M.; Yancopoulos, G.D.; Gullo, G.; Lowy, I.; Rietschel, P.Item EMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) >= 50%(2020) Sezer, A.; Kilickap, S.; Gumus, M.; Bondarenko, I.; Ozguroglu, M.; Gogishvilli, M.; Turk, H. M.; Cicin, I.; Bentsion, D.; Gladkov, O.; Clingan, P.; Sriuranpong, V.; Rizvi, N.; Li, S.; Lee, S.; Gullo, G.; Lowy, I.; Rietschel, P.; 0000-0002-6445-1439; AAD-2667-2020Item EMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) >= 50%(2020) Sezer, A.; Kilickap, S.; Gumus, M.; Bondarenko, I.; Ozguroglu, M.; Gogishvili, M.; Turk, H. M.; Cicin, I.; Bentsion, D.; Gladkov, O.; Clingan, P.; Sriuranpong, V.; Rizvi, N.; Li, S.; Lee, S.; Gullo, G.; Lowy, I.; Rietschel, P.; 0000-0002-6445-1439; AAD-2667-2020